Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Automated Immunosuppressive Drug Assays from Roche

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Roche enables immunosuppressive drug assays to be consolidated onto main laboratory automated platforms.

For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform.

The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory.

Tacrolimus and cyclosporine are important ISDs used in the maintenance therapy of transplant recipients.

Due to the significant pharmacokinetic variability between patients for these drugs, TDM and concentration controlled dosing are used to tailor therapy for individual patients, ensuring the ideal balance between efficacy and toxicity.

It is therefore paramount that tests used to monitor transplant patient’s response to therapy exhibit high quality performance and are efficient to run.

The new Roche tacrolimus and cyclosporine assays will provide performance with the proven Elecsys electrochemiluminescence (ECL) technology for reliable and trusted results.

The tests can be performed on any of the cobas modular platforms, including the cobas® 4000 and cobas®6000 analyzer series or the high volume cobas® 8000 modular analyzer series, allowing a wide range of assays to be performed on a single analytical platform for increased laboratory efficiency.

This includes serology assays, allowing clinicians to test donors and recipients for important infectious diseases, and organ function tests to monitor the health and recovery of transplant patients.

Fully automated laboratories can also benefit from Roche pre- and post- analytical solutions for rapid and convenient sample preparation, storage and retrieval.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Roche Award for Antibody-based Cancer Therapy Research
Researchers from academia throughout Europe are invited to participate.
Wednesday, May 15, 2013
Roche's Troponin T Nominated for International Inventor Award
European Patent Office nominates the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg.
Monday, June 11, 2012
New Findings in Drug-Induced Receptor Activity
The discovery that drugs targeting a single GPCR can differentially modulate distinct subsets of the receptor signaling repertoire is a very important step in drug discovery.
Wednesday, February 15, 2012
Scientific News
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos